- Home
- NBN vs MLTX Comparison
NBN vs MLTX Comparison
Compare NBN & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBN | MLTX |
|---|---|---|
| Founded | 1872 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 836.7M | 979.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NBN | MLTX |
|---|---|---|
| Price | $116.07 | $16.71 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $102.00 | $22.22 |
| AVG Volume (30 Days) | 126.4K | ★ 3.5M |
| Earning Date | 02-05-2026 | 02-25-2026 |
| Dividend Yield | ★ 0.04% | N/A |
| EPS Growth | ★ 38.19 | N/A |
| EPS | ★ 10.63 | N/A |
| Revenue | ★ $214,699,000.00 | N/A |
| Revenue This Year | $11.59 | N/A |
| Revenue Next Year | $11.26 | N/A |
| P/E Ratio | $10.74 | ★ N/A |
| Revenue Growth | ★ 36.17 | N/A |
| 52 Week Low | $78.17 | $5.95 |
| 52 Week High | $117.28 | $62.75 |
Technical Indicators
Market Signals| Indicator | NBN | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 67.93 | 59.35 |
| Support Level | $105.21 | $15.70 |
| Resistance Level | $113.47 | $18.80 |
| Average True Range (ATR) | 3.69 | 1.20 |
| MACD | 0.28 | 0.44 |
| Stochastic Oscillator | 79.86 | 73.51 |
Price Performance
Historical ComparisonAbout NBN Northeast Bank
Northeast Bank provides banking and financial services to individual and corporate customers in the United States. The firm conducts its loan-related activities through two primary channels: the Community Banking Division, and the Small Business Administration (SBA) National Division. Its loan portfolio comprises residential mortgage loans; multi-family and other commercial real estate loans; commercial and industrial loans, consumer loans, and small business administration loans. The firm also provides telephone banking, online banking, mobile banking, and remote deposit capture services. The revenue of the company is derived principally from interest and dividends from the bank.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.